IP Library Granted Patent US 12,115,134
Granted Patent B2
US 12,115,134 · App. 18/430,796 · Granted Oct 15, 2024

Compositions and methods for treating endocrine diseases and disorders

Inventors: Christopher Hanson (Mountain View, CA); William Harries (Boulder Creek, CA)
Assignee: Olfactive Biosolutions, LLC
A61K31/045A61K31/085A61K31/19A61K31/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,115,134
App. No.
18/430,796
Granted
Oct 15, 2024
Kind
B2
Abstract

Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate insulin secretion and suppress appetite by activating ectopic olfactory receptors. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes, and disorders, such as abnormal insulin secretion.

Claims (10)

1. A composition for treating an endocrine disease of a patient, comprising:

a GLP-1/PYY secretion composition comprising a delivery medium, 3-methylpentanoic acid and farnesol, said 3-methylpentanoic acid comprising an EC 50 value in said GLP-1/PYY secretion composition in the range of from about 10.0 μM to about 30.0 μM, said farnesol comprising an EC 50 value in said GLP-1/PYY secretion composition in the range of from about 0.4 μM to about 0.5 μM,

said GLP-1/PYY secretion composition adapted to induce glucagon-like peptide-1 (GLP-1) and peptide Y-Y (PYY) secretion and, thereby, increased insulin secretion in vivo, when said GLP-1/PYY secretion composition is delivered to said patient.

2. The composition of claim 1 , wherein said GLP-1/PYY secretion composition induces at least 50% activation of ectopic olfactory receptor family 51 subfamily E member 1 (OR51E1) in vivo when said GLP-1/PYY secretion composition is said delivered to said patient.

3. The composition of claim 1 , wherein said GLP-1/PYY secretion composition further comprises eugenol.

4. The composition of claim 3 , wherein said eugenol comprises an EC 50 value in said GLP-1/PYY secretion composition in the range of from about 1.0 μM to about 15.0 μM.

5. The composition of claim 1 , wherein said delivery medium comprises glycerin-based water.

6. The composition of claim 1 , wherein said delivery medium comprises ingestible matter.

7. The composition of claim 6 , wherein said ingestible matter is selected from the group consisting of an item of food and a beverage.

8. The composition of claim 1 , wherein said endocrine disease comprises type-2 diabetes mellitus.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2025
From: OLFACTIVE BIOSOLUTIONS, LLC
To: OLFACTIVE AI, INC.
Reel/Frame 070061/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2024
From: HANSON, CHRISTOPHER, MR.; HARRIES, WILLIAM, MR.
To: OLFACTIVE BIOSOLUTIONS, LLC
Reel/Frame 066392/0302 →
Continuity (2)
Provisional Application 63615100 · Dec 27, 2023
Related Publication 20240165061A1 · May 23, 2024